Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: A 12-week prospective study

Journal of Psychopharmacology

Volumn 24, Issue 8, 2010, Pages 1201-1207

  Segui J ^a   Lopez Munoz F ^b   Alamo C ^b   Camarasa, X ^c   Garcia Garcia P ^b   Pardo, A ^d  

^a HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

combination treatment; duloxetine; major depressive disorder; reboxetine; resistant depression

Indexed keywords

DULOXETINE; REBOXETINE;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSURIA; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; MULTICENTER STUDY; NERVOUSNESS; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; STOMACH DISCOMFORT; SWEATING; TASTE DISORDER; THERAPY EFFECT; TREMOR; XEROSTOMIA;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955161278     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109102641     Document Type: Article

References (74)

1. Agäera, LF, Rojo, JE, Ros, S., De la Gándara, J., De Pedro, JM (2005) Antidepressant combinations: epidemiological considerations. Acta Psychiatr Scand 112: 7-10.
2. Alamo, C., López-Muñoz, F., Rubio, G., García- García, P., Pardo, A. (2007) Combined treatment with reboxetine in depressed patients with no response to venlafaxine: a 6-week follow-up study. Acta Neuropsychiatr 19: 291-296.
3. Amsterdam, JD, Hornig-Rohan, M. (1996) Treatment algorithms in treatment-resistant depression. Clin North Am 19: 371-386.
4. Amsterdam, JD, García-España, F., Rosenzweig, M. (1997) Clomipramine augmentation in treatment-resistant depression. Depress Anxiety 5: 84-90.
5. Berzewski, H., Van Moffaert, M., Gagiano, CA (1997) Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol 7 (Suppl. 1). 37-47.
6. Bhatara, VS, Magnus, R., Lynn, P., Preskorn, S. (1998) Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in poly-pharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother 32: 889-891.
7. Blazer, DG, Kessler, RC, McGonagle, KA, Swartz, MS (1994) The prevalence and distribution of major depression in a National Community Sample: The National Comorbidity Survey. Am J Psychiatry 151: 979-986.
8. Bodkin, JA, Lasser, RA, Wines, JD, Gardner, DM, Baldessarini, RJ (1997) Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 58: 137-145.
9. Bymaster, FP, Dreshfield-Ahmad, LJ, Threlkeld, PG, Shaw, JL, Thompson, L., Nelson, DL, et al. (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25: 871-880.
10. Carpenter, LL, Jocic, Z., Hall, JM, Rasmussen, SA, Price, LH (1999) Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 60: 45-49.
11. Carpenter, LL, Yasmin, S., Price, LH (2002) A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 51: 183-188.
12. Carvalho, AF, Cavalcante, JL, Castelo, MS, Lima, MCO (2007) Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther 32: 415-428.
13. Craig, J. (2003) Managing treatment-resistant major depression. J Clin Psychiatry 64: 5-12.
14. De la Gándara, J., Rojo, JE, Ros, S., Agäera, L., de Pedro, JM (2005) Neuropharmacological basis of combining antidepressant. Acta Psychiatr Scand 112: 11-13.
15. De Montigny, C., Silverstone, PH, Debonnel, G., Blier, P., Bakish, D. (1999) Venlafaxine for treatment resistant depression: a Canadian multi-center, open label trial. J Clin Psychopharmacol 19: 401-406.
16. Delgado, PL, Brannan, SK, Mallinckrodt, CH, Tran, PV, McNamara, RK, Wang, F., et al. (2005) Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 66: 686-692.
17. Devarajan, S., Dursun, SM (2000) Citalopram plus reboxetine in treatment-resistant depression. Can J Psychiatr 45: 489-490.
18. Dodd, S., Horgan, D., Malhi, GS, Berk, M. (2005) To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord 89: 1-11.
19. Fagiolini, A., Kupfer, DJ (2003) Is treatment-resistant depression a unique subtype of depression ? Biol Psychiatry 53: 640-648.
20. Fava, M. (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatr 53: 649-659.
21. Fava, M., Rosenbaum, JF, McGrath, PJ, Stewart, JW, Amsterdam, JD, Quitkin, FM (1994) Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 151: 1372-1374.
22. Fleishaker, JC (2000) Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet 39: 413-427.
23. Frampton, JE, Plosker, GL (2007) Duloxetine. A review of its use in the treatment of major depressive disorder. CNS Drugs 21: 581-609.
24. Gaynes, B., Davis, L., Rush, J., Trivedi, M., Fava, M., Wisniewski, S. (2005) The aims and design of the sequenced treatment alternatives to relieve depression (STAR*D) Study. Prim Psychiatr 12: 36-41.
25. Gonul, AS, Akdeniz, F., Donat, O., Vahip, S. (2003) Selective serotonin reuptake inhibitors combined with venlafaxine in depressed patients who had partial response to venlafaxine: four cases. Prog Neuro-Psychopharmacol Biol Psychiatry 27: 889-891.
26. Gotto, J., Rapaport, MH (2005) Treatment options in treatment-resistant depression. Prim Psychiatry 12: 42-50.
27. Hannan, N., Hamzah, Z., Omoniyi Akinpeloye, H., Meagher, D. (2007) Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness. J Psychopharmacol 21: 161-164.
28. Hawley, CJ, Sivakumaran, T., Ochocki, M., Bevan, J. (2000) Coadministration therapy with reboxetine and serotonin specific reuptake inhibitors in twenty-four patients with major depression. 13th Congress of European College of Neuropsychopharmacology. Munich, Germany, 9-13 September.
29. Hirschfeld, RM, Montgomery, SA, Aguglia, E., Amore, M., Delgado, PL, Gastpar, M., et al. (2002) Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 63: 826-837.
30. Joffe, RT (1999) Substitution Therapy in Patients with Major Depression. CNS Drugs 11: 175-180.
31. Kelsey, JE (1997) Switching drug class after initial SSRI failure. J Clin Psychiatry 58: 326-327.
32. Kennedy, SH, McCann, SM, Masellis, M., McIntyre, RS, Raskin, J., McKay, G., et al. (2002) Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 63: 181-186.
33. Kessler, RC, Berglund, P., Demler, O., Jin, R., Merikangas, KR, Walters, EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 593-602. (Pubitemid 40973434)
34. Kornstein, SG, Wohlreich, MM, Mallinckrodt, CH, Watkin, JG, Stewart, DE (2006) Duloxetine efficacy for major depressive disorder in male vs. female patients: Data from 7 randomized, double-blind, placebo-controlled trials. J Clin Psychiatry 67: 761-770.
35. Kuhn, UD, Kirsch, M., Merkel, U., Eberhardt, A-M., Wenda, B., Maurer, I., et al. (2007) Reboxetine and cytochrome P450. Comparison with paroxetine treatment in humans. Int J Clin Pharmacol Ther 45: 36-46.
36. Lam, RW, Hossie, H., Solomons, K., Yatham, LN (2004) Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry 65: 337-340.
37. Lam, WL, Wan, D., Cohen, N., Kennedy, S. (2002) Combining antidepressant for treatment-resistant depression: a review. J Clin Psychiatry 63: 685-693.
38. Lepine, JP, Gastpar, M., Mendlewicz, J., Tylee, A. (1997) Depression in the community: The first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 12: 19-29.
39. López-Muñoz, F., Alamo, C., Rubio, G., García- García, P., Pardo, A. (2007) Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors. Pharmacopsychiatry 40: 14-19.
40. López-Muñoz, F., Rubio, G., Alamo, C., García- García, P., Pardo, A. (2006) Reboxetine addition in patients with mirtazapine-resistant depression: a case series. Clin Neuropharmacol 29: 192-196.
41. Lucca, A., Serretti, A., Smeraldi, E. (2000) Effect of reboxetine augmentation in SRRI resistant patients. Hum Psychopharmacol Clin Exp 15: 143-145.
42. Malhi, GS, Ng, F., Berk, M. (2008) Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression. Aust N Z J Psychiatry 42: 346-349.
43. Malhi, GS, Parker, GB, Crawford, J., Wilhelm, K., Mitchell, PB (2005) Treatment-resistant depression: Resistant to definition ? Acta Psychiatr Scand 112: 302-309.
44. Mallinckrodt, CH, Prakash, A., Andorn, AC, Watkin, JG, Wohlreich, MM (2006) Duloxetine for the treatment of major depressive disorder: A closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 40: 337-348.
45. Messer, T., Schmauss, M., Lambert-Baumann, J. (2005) Efficacy and tolerability of reboxetine in depressive patients treated in routine clinical practice. CNS Drugs 19: 43-54.
46. Nelson, JC (2000) Augmentation strategies in depression. J Clin Psychiatry 61 (Suppl. 2). 13-19.
47. Nelson, JC, Mazure, CM, Bowers, MB, Jatlow, PI (1991) A preliminary open study if the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 48: 303-307.
48. Nelson, JC, Mazure, CM, Jatlow, PI, Bowers, MB, Price, LH (2004) Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatr 55: 296-300.
49. Nemeroff, CB (1997) Augmentation strategies in patients with refractory depression. Depression 4: 169-181.
50. Nierenberg, AA, Amsterdam, JD (1990) Resistant depression: Definition and treatment approaches. J Clin Psychiatry 51: S39 - S47.
51. Nierenberg, AA, Feighner, J., Rudolph, R. (1994) Venlafaxine for treatment resistant unipolar depression. J Clin Psychopharmacol 14: 419-423.
52. Papakostas, GI, Worthington, JJ, Iosifescu, DV, Kinrys, G., Burns, AM, Fisher, LB, et al. (2006) The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety 23: 178-181.
53. Ravindran, LN, Eisfeld, BS, Kennedy, SH (2008) Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function. J Clin Psychopharmacol 28: 107-108.
54. Rojo, JE, Ros, S., Agäera, L., de la Gándara, J., de Pedro, JM (2005) Combined antidepressant: clinical experience. Acta Psychiatr Scand 112: 25-31.
55. Ros, S., Agäera, L., De la Gándara, J., Rojo, JE, De Pedro, JM (2005) Potentiation strategies for treatment-resistant depression. Acta Psychiatr Scand 112: 14-24.
56. Rubio, G., San, L., López-Muñoz, F., Alamo, C. (2004) Reboxetine adjunct for partial or nonresponders to antidepressant treatment. J Affect Disord 81: 67-72.
57. Rubio, G., San, L., López-Muñoz, F., García- García, P., Álamo, C. (2003) Tratamiento de combinación con reboxetina en pacientes con depresión mayor no respondedores o con respuesta parcial a inhibidores selectivos de la recaptación de serotonina. Actas Esp Psiquiatr 31: 315-324.
58. Sáiz-Ruiz, J., Ibañez, A., Díaz-Marsá, M., Arias, F., Padín, J., Martín-Carrasco, M., et al. (1999) Eficacia de la venlafaxina en pacientes depresivos resistentes o que no toleran inhibidores selectivos de la recaptación de serotonina. Psiquiatr Biol 6: 106-112.
59. Schatzberg, AF, Cole, JO, Cohen, BM, Altesman, RI, Sniffin, CM (1983) Survey of depressed patients who have failed to respond to treatment. In: Davis, JM, Maas, JW (eds). The Affective Disorders. Washington (DC): American Psychiatric Press, pp. 73-85.
60. Serretti, A., Lucca, A., Cusin, C., Smeraldi, E. (2001) Associazione di reboxetine nella depressione resistente a SSRI effect of reboxetine augmentation in SSRI resistant patients. Giorn Ital Psicopatol 7: 9-14.
61. Shelton, RC, Andorn, AC, Mallinckrodt, CH, Wohlreich, MM, Raskin, J., Watkin, JG, et al. (2007) Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. Int Clin Psychopharmacol 22: 348-355.
62. Sokolov, STH, Joffe, RT (1995) Practical guidelines for combination drug therapy of treatment-resistant depression. CNS Drugs 4: 341-350.
63. Spier, SA (1998) Use of bupropion with SRIs and venlafaxine. Depress Anxiety 7: 73-75.
64. Stanley, B. (1988) An integration of ethical and clinical considerations in the use of placebos. Psychopharmacol Bull 24: 180-220.
65. Tanum, L. (2000) Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand 101 (Suppl. 402). 37-40.
66. Trivedi, MH, Rush, AJ, Wisniewski, SR, Nierenberg, AA, Warden, D., Ritz, L., et al. (2006 a) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28-40.
67. Trivedi, MH, Fava, M., Wisniewski, SR, Thase, ME, Quitkin, F., Warden, D., et al. (2006 b) Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354: 1243-1252.
68. Versiani, M., Mohammed, A., Guy, CH (2000) Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 20: 28-34.
69. Wijeratne, C., Sachdev, P. (2008) Treatment-resistant depression: critique of current approaches. Aust N Z J Psychiatry 42: 752-762.
70. Wohlreich, MM, Mallinckrodt, CH, Prakash, A., Watkin, JG, Carter, WP (2007 a) Duloxetine for the treatment of major depressive disorder: Safety and tolerability associated with dose escalation. Depress Anxiety 24: 41-52.
71. Wohlreich, MM, Wiltse, CG, Desaiah, D., Ye, W., Robinson, RL, Kroenke, K., et al. (2007 b) Duloxetine in practice-based clinical settings: Assessing effects on the emotional and physical symptoms of depression in an open-label, multicenter study. Prim Care Companion J Clin Psychiatry 9: 271-279.
72. Wong, EHF, Sonders, MS, Amara, SG, Tinholt, PM, Piercey, MFP, Hoffmann, WP, et al. (2000) Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47: 818-829.
73. Zajecka, JM, Jeffriess, H., Fawcett, J. (1995) The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J Clin Psychiatry 56: 338-343.
74. Zisook, S., Rush, AJ, Haight, BR, Clines, DC, Rockett, CB (2006) Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 59: 203-210.